Proton Beam Therapy for Oesophageal Cancer: Engagement Report for Clinical Commissioning Policies – NHS England and NHS Improvement

NHS England has reviewed the evidence to treat oesophageal cancer with proton beam therapy (PBT) in adults and have concluded that there is not enough evidence to make the treatment available through routine commissioning.

Proton Beam Therapy for Oesophageal Cancer: Clinical Priorities Advisory Group – NHS England and NHS Improvement

This policy statement recommends that proton beam therapy (PBT), a form of radiotherapy, should not be made routinely available for the treatment of oesophageal cancer in adults. This treatment is not currently available in this indication and therefore does not

Proton Beam Therapy for Oesophageal Cancer: Engagement Report for Clinical Commissioning Policies – NHS England and NHS Improvement

NHS England has reviewed the evidence to treat oesophageal cancer with proton beam therapy (PBT) in adults and have concluded that there is not enough evidence to make the treatment available through routine commissioning.

Proton Beam Therapy for Oesophageal Cancer: Policy Statement – NHS England and NHS Improvement

NHS England has reviewed the evidence to treat oesophageal cancer with proton beam therapy (PBT) in adults and have concluded that there is not enough evidence to make the treatment available through routine commissioning.

Why do patients with a curative treatment plan for oesophago-gastric cancer not go on to receive surgery? – National Oesophago-Gastric Cancer Audit

The main curative treatment for patients with localised OG cancer is to remove the tumour with surgery (usually along with receiving chemotherapy or chemo-radiotherapy). As many OG patients are diagnosed with the condition at an advanced stage, only 30% of

Clinical Commissioning Policy: 18Ffluorodeoxyglucose (FDG) positron emission tomography-computedtomography (PET CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages) – NHS England

NHS England will not routinely commission 18F-FDG-PET CT as part of radical radiotherapy treatment planning for oesophageal cancer in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the

National Oesophago-Gastric Cancer Audit Report 2017 – Healthcare Quality Improvement Partnership

This 2017 Annual Report from the National Oesophago-Gastric Cancer Audit provides the most up-to-date information on the care and outcomes of patients diagnosed with OG cancer or oesophageal high grade dysplasia.